- Home
- UNCY vs APLT Comparison
UNCY vs APLT Comparison
Compare UNCY & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- APLT
- Stock Information
- Founded
- UNCY 2016
- APLT 2016
- Country
- UNCY United States
- APLT United States
- Employees
- UNCY N/A
- APLT N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- UNCY Health Care
- APLT Health Care
- Exchange
- UNCY Nasdaq
- APLT Nasdaq
- Market Cap
- UNCY 74.2M
- APLT 69.0M
- IPO Year
- UNCY 2021
- APLT 2019
- Fundamental
- Price
- UNCY $4.36
- APLT $0.47
- Analyst Decision
- UNCY Strong Buy
- APLT Buy
- Analyst Count
- UNCY 4
- APLT 6
- Target Price
- UNCY $63.75
- APLT $6.10
- AVG Volume (30 Days)
- UNCY 483.3K
- APLT 870.5K
- Earning Date
- UNCY 08-14-2025
- APLT 11-06-2025
- Dividend Yield
- UNCY N/A
- APLT N/A
- EPS Growth
- UNCY N/A
- APLT N/A
- EPS
- UNCY N/A
- APLT N/A
- Revenue
- UNCY N/A
- APLT $121,000.00
- Revenue This Year
- UNCY N/A
- APLT N/A
- Revenue Next Year
- UNCY $3,131.28
- APLT $5,931.24
- P/E Ratio
- UNCY N/A
- APLT N/A
- Revenue Growth
- UNCY N/A
- APLT N/A
- 52 Week Low
- UNCY $3.24
- APLT $0.30
- 52 Week High
- UNCY $11.00
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- UNCY 49.39
- APLT 48.57
- Support Level
- UNCY $4.15
- APLT $0.46
- Resistance Level
- UNCY $4.35
- APLT $0.53
- Average True Range (ATR)
- UNCY 0.24
- APLT 0.03
- MACD
- UNCY 0.05
- APLT -0.01
- Stochastic Oscillator
- UNCY 53.76
- APLT 18.78
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.